Johnson & Johnson and Pfizer Inc.’s experimental Alzheimer’s medicine may reduce the development of tau tangles in the brain, a hallmark trait of the degenerative condition, a small study suggested.
Go here to read the rest:
J&J Alzheimer’s ... continue reading
SOUTH SAN FRANCISCO, Calif., Jan. 26, 2012 /PRNewswire/ – Janssen Alzheimer Immunotherapy, together with its collaborator on the Alzheimer's Immunotherapy Program (AIP), Pfizer Inc. (NYSE: PFE – News), and the …
Read the rest here:
Alzheimer's Challenge 2012: ... continue reading
Public Citizen has petitioned the FDA to ban high doses of the Alzheimer’s drug Aricept, claiming the risks far exceed the benefits. The drug, made by Pfizer and Elsai, has been approved at doses of 5 to 10 milligrams for patients with mild to moderate Alzheimer’s, and at 10 to ... continue reading
CHICAGO and NEW YORK, Dec. 6, 2010 /PRNewswire/ — With as many as 10 million U.S. baby boomers at risk for developing Alzheimer’s,(1) the Alzheimer’s Association and Pfizer (NYSE: PFE) are collaborating to help raise awareness of Alzheimer’s disease by emphasizing to all Americans, “It’s Time to Face Alzheimer’s.” The ... continue reading
A promising Alzheimer’s disease drug Pfizer Inc. and a partner are developing failed to work in a late-stage study, a startling disappointment after the potential blockbuster kept symptoms from worsening for a year in a prior test.
Originally posted here:
... continue reading